Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-[gamma]/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

• Published in: Vaccine Vol. 28; no. 31; p. 5135
• Main Authors: Cummings, James F, Spring, Michele D, Schwenk, Robert J, Ockenhouse, Christian F, Kester, Kent E, Polhemus, Mark E, Walsh, Douglas S, Yoon, In-Kyu, Prosperi, Christine, Juompan, Laure Y, Lanar, David E, Krzych, Urszula, Hall, B Ted, Ware, Lisa A, Stewart, V Ann, Williams, Jack, Dowler, Megan, Nielsen, Robin K, Hillier, Collette J, Giersing, Birgitte K, Dubovsky, Filip, Malkin, Elissa, Tucker, Kathryn, Dubois, Marie-Claude, Cohen, Joe D, Ballou, W Ripley, Jr, D Gray Heppner
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 12.07.2010
• Subjects: Amino acids; Drug dosages; Family medical history; Hepatitis; Immunization; Inventors; Liver; Lymphocytes; Malaria; Pain; Proteins; Review boards; Vaccines; Vector-borne diseases; United States > US; Maryland
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2009.08.046

Plasmodium falciparumLiver Stage Antigen 1 (LSA-1) is a pre-erythrocytic stage antigen. Our LSA-1 vaccine candidate is a recombinant protein with full-length C- and N-terminal flanking domains and two of the 17 amino acid repeats from the central repeat region termed "LSA-NRC." We describe the first Phase I/II study of this recombinant LSA-NRC protein formulated with either the AS01 or AS02 adjuvant system. We conducted an open-label Phase I/II study. Thirty-six healthy malaria-naïve adults received one of four formulations by intra-deltoid injection on a 0 and 1 month schedule; low dose (LD) LSA-NRC/AS01:10μg LSA-NRC/0.5ml AS01 (n=5), high dose (HD) LSA-NRC/AS01: 50μg LSA-NRC/0.5ml AS01 (n=13); LD LSA-NRC/AS02: 10μg LSA-NRC/0.5ml AS02 (n=5) and HD LSA-NRC/AS02: 50μg LSA-NRC/0.5ml AS02 (n=13). Two weeks post-second immunization, the high dose vaccinees and 6 non-immunized infectivity controls underwent experimental malaria sporozoite challenge. The vaccines showed a reassuring safety profile but were moderately reactogenic. There were no serious adverse events. All subjects seroconverted after the first immunization. Following the second immunization, LSA-1-specific CD4+ T cells producing two cytokines (IL-2 and IFN-γ) were found by intra-cellular staining in all subjects in the LD LSA-NRC/AS01B group and in 3 of 5 subjects in the LD LSA-NRC/AS02 group. In contrast, the HD LSA-NRC/AS01 and HD LSA-NRC/AS02 group subjects had fewer LSA-1-specific CD4+ T cells, and minimal to no IFN-γ responses. There was no increase in LSA-1-specific CD8+ T cells found in any group. Per protocol, 22 high dose vaccinees, but no low dose vaccinees, underwentP. falciparumhomologous malaria challenge (3D7 clone). All vaccinees became parasitemic and there was no delay in their pre-patent period versus controls (p=0.95). LSA-NRC/AS01 and LSA-NRC/AS02 elicited antigen-specific antibody and CD4+ T cell responses, but elicited no protective immunity. Although the optimal antigen dose of LSA-NRC may not have been selected for the challenge portion of the protocol, further vaccine development based upon LSA-1 should not be excluded and should include alternative vaccine platforms able to elicit additional effector mechanisms such as CD8+ T cells.